Public record

Zepbound: the public record

1 table from US federal sources. Latest data date: 2025.

Each table is computed from the named federal dataset as of its data date; the method is under each one.

Medicaid

Medicaid prescriptions for Zepbound by state

State Medicaid programmes paid for 1,721,606 Zepbound prescriptions in 2025, with $1.81B reimbursed before rebates. California reported the most (701,827), followed by Massachusetts (208,115) and Pennsylvania (207,261); 46 states and territories reported any.

Medicaid prescriptions for Zepbound by state: the figures
MeasureValueNote
Prescriptions paid by Medicaid, 20251,721,606
Total reimbursed before rebates, 2025$1.81B
States and territories reporting46with at least one count CMS did not suppress
California701,827 prescriptions$744.2M reimbursed
Massachusetts208,115 prescriptions$215.7M reimbursed
Pennsylvania207,261 prescriptions$222.0M reimbursed
Michigan161,929 prescriptions$168.1M reimbursed
Missouri125,387 prescriptions$132.8M reimbursed

Source: CMS, Medicaid State Drug Utilization Data 2025, data as of 2025

How this was calculated

Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.

Scope: Zepbound only (brand-name tirzepatide), fee-for-service and managed care, 2025

Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.

Download the data (CSV)

Articles on Zepbound